携带ATM、CHEK2或PALB2致病性变异的乳腺癌、结直肠癌和胰腺癌患者死亡率
研究纳入2013-2019年SEER登记(加州和乔治亚州)的70272例乳腺癌、5822例结直肠癌和1861例胰腺癌患者,链接胚系基因检测结果并随访至2021年。携带ATM、CHEK2或PALB2致病性变异的患者,其乳腺癌、结直肠癌和胰腺癌死亡率与所有接受基因检测的同癌种患者平均风险相比无差异。
要点
- 携带ATM、CHEK2或PALB2致病性变异的乳腺癌、结直肠癌和胰腺癌患者死亡率与基因检测患者平均水平无差异。
- 三阴性乳腺癌中ATM变异固定效应模型HR 3.7,随机效应模型HR 1.2,后者减少过拟合。
- BRCA1/2变异三阴性乳腺癌死亡风险较低(固定HR 0.6,随机HR 0.7);林奇综合征基因变异结直肠癌死亡风险较低(固定HR 0.5,随机HR 0.7)。
核心结论
- 携带ATM、CHEK2或PALB2致病性变异的患者,其乳腺癌、结直肠癌和胰腺癌死亡率与同癌种接受基因检测患者的平均风险相似。
研究设计与样本
- 研究纳入2013-2019年在加州和乔治亚州SEER登记、年龄20岁及以上、诊断为乳腺癌、结直肠癌或胰腺癌的患者,链接四个临床实验室的胚系基因检测结果并随访至2021年。
- 共分析70272例乳腺癌(48473例雌激素受体/孕激素受体阳性且HER2阴性、9957例HER2阳性、11842例三阴性)、5822例结直肠癌和1861例胰腺癌患者,平均随访3.9年。
- 采用多变量模型分析癌症死亡率,以所有接受基因检测的同癌种患者平均风险为参照组,每种癌症分别建模,随后构建癌症类型与所有协变量交互的单一模型;除固定效应模型外,还使用随机效应模型作为正则化方法以减少过拟合。
主要发现
- 携带ATM、CHEK2或PALB2致病性变异的患者,乳腺癌、结直肠癌或胰腺癌死亡率无差异。
- 三阴性乳腺癌中ATM变异患者在固定效应模型中死亡率似乎更高(HR 3.7,95%CI 1.8-7.8),但在减少过拟合的随机效应模型中无差异(HR 1.2,95%CI 0.8-1.6)。
- BRCA1/2变异三阴性乳腺癌患者在两种模型中死亡率均较低(固定HR 0.6,95%CI 0.5-0.9;随机HR 0.7,95%CI 0.6-0.8)。
- 林奇综合征基因变异结直肠癌患者在两种模型中死亡率均较低(固定HR 0.5,95%CI 0.4-0.8;随机HR 0.7,95%CI 0.5-0.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Oncologists encounter patients with pathogenic variants (PVs) in ATM, CHEK2, or PALB2, but little is known about their cancer mortality. METHODS: Patients who were 20 years or older, diagnosed in 2013-2019 with breast, colorectal, or pancreatic cancer, and reported to SEER registries in California and Georgia were linked to germline genetic testing results from four clinical laboratories and followed through 2021. Multivariable models of cancer mortality were fit; for each cancer, the reference group was the average hazard across all genetically tested patients with that diagnosis. Each cancer was modeled separately, followed by a single model that interacted the cancer type with all covariates. In addition to fixed effects models, random effects models were used as a regularization approach to reduce overfitting. RESULTS: A total of 70,272 tested patients with breast (48,473 estrogen receptor-/progesterone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative; 9,957 HER2-positive; 11,842 triple-negative) cancer, 5,822 with colorectal cancer, and 1,861 with pancreatic cancer were analyzed; the mean follow-up was 3.9 years. Patients with ATM, CHEK2, or PALB2 PVs had no differences in breast, colorectal, or pancreatic cancer mortality. Patients with ATM PVs in triple-negative breast cancer appeared to have higher mortality in fixed effects models (hazard ratio [HR], 3.7 [95% CI, 1.8 to 7.8]), but not in random effects models (HR, 1.2 [95% CI, 0.8 to 1.6]) that reduce overfitting. Patients with BRCA1/2 PVs had lower triple-negative breast cancer mortality in both models (fixed HR, 0.6 [95% CI, 0.5 to 0.9], random HR, 0.7 [95% CI, 0.6 to 0.8]). Patients with Lynch syndrome gene PVs had lower colorectal cancer mortality in both models (fixed HR, 0.5 [95% CI, 0.4 to 0.8], random HR, 0.7 [95% CI, 0.5 to 0.9]). CONCLUSION: Patients with ATM, CHEK2, or PALB2 PVs had similar breast, colorectal, and pancreatic cancer mortality to the average genetically tested patient with their cancer type.
引用
- Veenstra CM, Abrahamse P, Hamilton AS, et al. Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2. J Clin Oncol. 2025. PMID: 40020204. doi:10.1200/JCO-24-02442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。